Research programme: ERK1/2 inhibitors - GEn1E Lifesciences
Alternative Names: Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) immunomodulators - GEn1E LifesciencesLatest Information Update: 28 Aug 2026
At a glance
- Originator University of Maryland, Baltimore
- Developer GEn1E Lifesciences
- Class Anti-inflammatories; Antineoplastics
- Mechanism of Action Extracellular signal-regulated MAP kinase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Lung disorders; Musculoskeletal disorders
Most Recent Events
- 28 Aug 2026 No recent reports of development identified for research development in Cancer in USA
- 28 Aug 2026 No recent reports of development identified for research development in Lung disorders in USA
- 28 Aug 2026 No recent reports of development identified for research development in Musculoskeletal-disorders in USA